A Comprehensive Scientific Monograph on Somatotropin (DB00052)

Expert Persona: PhD Researcher, Author of Technical Papers

Executive Summary

Somatotropin, or recombinant human growth hormone (rhGH), represents a cornerstone of modern endocrine therapy and a landmark achievement in biotechnology. This monograph provides a comprehensive scientific review of Somatotropin, identified by DrugBank ID DB00052 and CAS Number 12629-01-5. Its history is a compelling narrative of medical progress, evolving from a scarce, high-risk biological extract derived from human cadavers to a safe, pure, and abundantly available therapeutic protein produced via recombinant DNA technology. This transition was critically accelerated by the public health crisis of iatrogenic Creutzfeldt-Jakob disease in the 1980s, which necessitated a safer manufacturing alternative.

The primary physiological role of Somatotropin is the regulation of somatic growth and metabolism. Its mechanism of action is mediated through the Growth Hormone Receptor (GHR), activating the intracellular JAK-STAT signaling pathway. This leads to a cascade of cellular events, most notably the hepatic production of Insulin-like Growth Factor-1 (IGF-1), which mediates the majority of GH's anabolic and growth-promoting effects. Somatotropin exerts pleiotropic effects on metabolism, functioning as a potent nutrient-partitioning agent: it stimulates protein synthesis and lipolysis while inducing a state of relative insulin resistance to conserve glucose.

Clinically, Somatotropin is approved by global regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a wide range of indications. In pediatric populations, it is the standard of care for growth failure due to Growth Hormone Deficiency (GHD), Turner syndrome, Noonan syndrome, Prader-Willi syndrome, and other conditions causing short stature. In adults, it serves as a replacement therapy for GHD and is used to treat specific conditions such as HIV-associated wasting and short bowel syndrome.

The safety profile of Somatotropin is well-characterized and considered manageable when prescribed for approved indications and with appropriate clinical monitoring. The most significant risks are confined to specific, high-risk subpopulations, such as critically ill patients or children with Prader-Willi syndrome who are severely obese. For the majority of patients, adverse effects are primarily related to its metabolic actions and fluid retention, which are typically dose-dependent. The future of Somatotropin therapy is focused on improving patient adherence and quality of life through the development and approval of long-acting, once-weekly formulations, marking the next evolution in managing growth-related disorders.

1. Introduction and Historical Development

The history of Somatotropin is a powerful case study in medical innovation, marked by pioneering discoveries, a devastating public health crisis, and the ultimate triumph of biotechnology. The journey from a rare, tissue-derived extract to a globally available recombinant protein has fundamentally transformed the management of growth disorders.

1.1 From Pituitary Extract to Biotechnology: The Discovery of Growth Hormone

The scientific journey toward growth hormone therapy began in the early 20th century with the recognition of the pituitary gland's central role in somatic growth.[1] Throughout the 1940s and 1950s, researchers, including Choh Hao Li and Harold Papkoff, successfully isolated growth hormones from various animal species.[2] A crucial discovery during this period was the hormone's profound species-specificity; it became clear that humans respond only to growth hormone derived from primates, rendering animal sources therapeutically useless for human conditions.[2]

This specificity presented a formidable challenge, as the only viable source was the pituitary glands of human cadavers. A landmark moment occurred in 1958 when Dr. Maurice Raben administered this cadaver-derived human growth hormone (c-hGH) to a boy with pituitary dwarfism, resulting in a clinically significant increase in height.[1] This success established the therapeutic potential of GH and offered hope to thousands of children with severe growth deficiencies. However, the supply was extraordinarily limited. To manage this scarce resource, the National Pituitary Agency (NPA) was established in the United States in 1963 to oversee the collection of pituitary glands and the distribution of c-hGH for approved research and treatment protocols.[1] The therapy was reserved for only the most severe cases of GHD, with hundreds of pituitary glands required to treat a single patient for one year.[6]

1.2 The Creutzfeldt-Jakob Disease Crisis and the Cessation of Cadaveric hGH

The era of cadaver-derived hGH came to an abrupt and tragic end in 1985. It was discovered that some batches of c-hGH were contaminated with prions—misfolded, infectious proteins that cause Creutzfeldt-Jakob Disease (CJD), a rare, untreatable, and universally fatal neurodegenerative disorder.[2] The transmission of CJD through a medical treatment, known as iatrogenic CJD (iCJD), created a global public health crisis.

Cases began to emerge in patients who had received c-hGH therapy years or even decades earlier, highlighting the disease's alarmingly long incubation period, which can exceed 40 years.[9] As of August 2022, 81 cases of iCJD linked to c-hGH treatment have been identified in the United Kingdom alone, with dozens more reported worldwide.[8] In response to this discovery, the U.S. Food and Drug Administration (FDA) and other global health authorities immediately halted the distribution of all c-hGH products in 1985, leaving patients with GHD without a viable treatment option.[7]

1.3 The Advent of Recombinant DNA Technology and the Approval of the First Synthetic Somatropin

The cessation of c-hGH therapy created a critical therapeutic vacuum that was, by a fortunate coincidence of timing, filled by the nascent field of biotechnology. The scientific groundwork had been laid years earlier with the elucidation of hGH's 191-amino acid structure in 1972 and the successful cloning of the hGH gene in 1979.[1] Pioneering biotechnology companies, notably Genentech, had been developing methods to insert the human gene for GH into bacteria, effectively turning microorganisms like

Escherichia coli into miniature factories for producing the hormone.[7]

This recombinant DNA (rDNA) technology offered a solution that was not only scalable but also inherently safe from the risk of prion contamination. The public health emergency of the CJD crisis acted as a powerful catalyst, accelerating the regulatory review and adoption of this novel technology. In October 1985, a mere six months after the ban on c-hGH, the FDA approved Genentech's Protropin® (somatrem), the first synthetic version of hGH.[7] This was only the second recombinant pharmaceutical ever approved in the U.S. and a pivotal moment in medicine. The approval of recombinant Somatotropin did not just provide a replacement therapy; it ensured a safe, pure, and virtually limitless supply, transforming GH from a rare and risky treatment into a widely accessible and safe therapeutic agent. This technological leap saved an entire class of therapy from obsolescence and paved the way for the expansion of its clinical applications far beyond what was imaginable in the era of cadaver-derived hormone.[5]

2. Molecular Profile and Biological Function

Somatotropin is a complex polypeptide hormone whose structure and regulation are finely tuned to control growth and metabolism. Its unique biological properties, particularly its species-specificity, were a driving force behind its biotechnological development.

2.1 Structure, Isoforms, and Physicochemical Properties

Endogenous human growth hormone, and its recombinant form Somatotropin, is a single-chain polypeptide hormone.[3] The predominant and most biologically active isoform is a 191-amino acid protein with a molecular weight of approximately 22,124 daltons.[3] Its tertiary structure is characterized by a bundle of four alpha-helices, a conformation that is essential for its functional interaction with the growth hormone receptor.[3] The molecule is stabilized by two highly conserved intramolecular disulfide bonds that are critical for maintaining its biological activity.[16]

The pituitary gland secretes several molecular isoforms of GH. A significant variant is a 20 kDa isoform, which arises from alternative splicing of the GH1 gene transcript and lacks the amino acid residues from position 32 to 46.[3] This 20 kDa isoform is present in circulation in a relatively constant ratio to the 22 kDa form and exhibits reduced affinity for the GH receptor.[3] Other minor isoforms, including a glycosylated 23-24 kDa variant, have also been identified, particularly in post-exercise states.[3]

The development of the first recombinant hGH, Protropin® (somatrem), resulted in a molecule with 192 amino acids, containing the native 191-amino acid sequence plus an additional N-terminal methionine residue, which was a byproduct of the E. coli expression system.[14] While biologically active, this variant was associated with a higher incidence of antibody formation. Subsequent advancements in biotechnology have allowed for the production of recombinant Somatotropin that is identical to the native 191-amino acid sequence, eliminating this issue.[14]

The fundamental identifying and chemical characteristics of Somatotropin are consolidated in Table 1.

Table 1: Key Physicochemical Properties of Somatotropin

Parameter	Value	Source(s)
Official Name	Somatotropin	16
Synonyms	Human Growth Hormone (hGH), Somatropin	3
DrugBank ID	DB00052
CAS Number	12629-01-5	16
Type	Biotech
Molecular Formula	C990​H1529​N263​O299​S7​	16
Molecular Weight	22124.12 Da	3
Amino Acid Count	191 (Major Isoform)	3
Structure	Single-chain polypeptide; 4 α-helices; 2 disulfide bonds	3
Physical Form	Lyophilized white powder	21
Solubility	Soluble in weak acidic or alkaline buffers; insoluble in water	16

2.2 Genetics and Endogenous Regulation of Human Growth Hormone

The genetic blueprint for human growth hormone is located on the long arm of chromosome 17, in the q22-24 region.[3] This locus contains a cluster of five related genes:

GH1 (or GH-N), which codes for the primary form of GH synthesized in the pituitary gland; GH2 (or GH-V), which codes for a placental variant of GH; and three genes for human chorionic somatomammotropin (placental lactogen). Together, these genes form a family of homologous hormones with overlapping growth-promoting and lactogenic activities.[3]

Endogenous hGH is synthesized, stored in secretory granules, and released by specialized acidophilic cells called somatotrophs, which are located in the lateral wings of the anterior pituitary gland.[3] The secretion of GH is not continuous but occurs in a distinct pulsatile manner, a pattern critical for its biological effects.[14] This pulsatility is governed by a sophisticated neuroendocrine feedback system orchestrated by the hypothalamus.[17]

The primary regulators are two hypothalamic hormones:

1. Growth Hormone-Releasing Hormone (GHRH): A peptide that binds to the GHRH receptor on somatotrophs, stimulating both the synthesis and secretion of GH.[17]
2. Somatostatin (also known as Somatotropin Release-Inhibiting Factor, SRIF): A peptide that inhibits the release of GH from the pituitary, acting as a functional antagonist to GHRH.[17]

This central axis is further modulated by other signals:

• Ghrelin: A peptide hormone primarily secreted by the stomach in response to hunger. Ghrelin is a potent stimulator of GH secretion, binding to receptors on somatotrophs to trigger GH release.[17]
• Insulin-like Growth Factor-1 (IGF-1): Produced mainly by the liver in response to GH stimulation, IGF-1 is the principal mediator of the negative feedback loop. High levels of IGF-1 suppress GH secretion both directly at the pituitary and indirectly by stimulating the release of somatostatin and inhibiting the release of GHRH from the hypothalamus.[17]

This intricate regulatory network ensures that GH is released in sharp pulses, with the most significant secretory bursts occurring shortly after the onset of deep sleep.[14] Factors such as exercise, stress, hypoglycemia, and certain amino acids also stimulate GH release.[14] The species-specificity of Somatotropin, where only human and Old World monkey GH can effectively bind to the human receptor, represented a fundamental biological barrier in early therapeutic development.[3] Unlike insulin, which could be sourced from porcine or bovine pancreases, no non-primate animal alternative existed for hGH. This made the development of recombinant technology an absolute necessity following the CJD crisis, as it was the only viable path forward to ensure a safe and sustainable supply.

3. Mechanism of Action and Pharmacodynamics

Somatotropin's physiological effects are diverse, encompassing the stimulation of linear growth and profound modulation of protein, lipid, and carbohydrate metabolism. These actions are initiated through a specific cell surface receptor and are propagated by a cascade of intracellular signaling events, with Insulin-like Growth Factor-1 (IGF-1) playing a central role as a downstream mediator.

3.1 Signal Transduction: The Growth Hormone Receptor and the JAK-STAT Pathway

The biological actions of Somatotropin are initiated by its binding to the Growth Hormone Receptor (GHR), a 620-amino acid transmembrane protein that is a member of the Type I cytokine receptor superfamily.[26] The GHR exists on the cell surface as a pre-formed homodimer.[27] The binding of a single molecule of GH to the extracellular domains of two GHR molecules induces a precise conformational change in the dimer, which is the critical activation step.[27]

This ligand-induced reorientation activates the non-receptor tyrosine kinase, Janus Kinase 2 (JAK2), which is constitutively associated with the intracellular domain of the GHR.[28] Upon activation, JAK2 molecules phosphorylate each other (auto-phosphorylation) and then phosphorylate specific tyrosine residues within the GHR's intracellular domain.[29]

These newly phosphorylated tyrosine sites on the GHR serve as high-affinity docking sites for a family of latent cytoplasmic transcription factors known as Signal Transducers and Activators of Transcription (STATs).[17] For GH signaling, the most important members are STAT1, STAT3, and particularly STAT5.[17] Once docked to the receptor, the STAT proteins are themselves phosphorylated by the activated JAK2. This phosphorylation causes the STAT proteins to dissociate from the receptor, form homo- or heterodimers, and translocate to the cell nucleus.[17] Inside the nucleus, these STAT dimers bind to specific DNA response elements in the promoter regions of target genes, thereby regulating their transcription and initiating the cellular responses to GH.[30]

3.2 The Central Role of Insulin-Like Growth Factor-1 (IGF-1)

While GH has direct effects on some tissues, a majority of its growth-promoting actions are mediated indirectly through the production of Insulin-like Growth Factor-1 (IGF-1), a concept known as the "Somatomedin Hypothesis".[31] The activation of the JAK-STAT pathway in hepatocytes (liver cells) is the primary stimulus for the transcription of the

IGF-1 gene and the subsequent secretion of IGF-1 protein into the circulation.[17]

Once in the bloodstream, IGF-1 has a much longer half-life than GH because it is stabilized within a ternary complex composed of IGF-1, IGF-Binding Protein-3 (IGFBP-3), and an Acid-Labile Subunit (ALS).[19] The synthesis of both IGFBP-3 and ALS is also stimulated by GH, providing an additional layer of regulation.[19]

IGF-1 exerts its effects by binding to its own specific receptor, the IGF-1 receptor (IGF-1R), which is a transmembrane tyrosine kinase structurally similar to the insulin receptor.[17] Activation of the IGF-1R triggers intracellular signaling cascades, including the Phosphatidylinositol 3-Kinase (PI3K)/AKT pathway and the Ras/Mitogen-Activated Protein Kinase (MAPK) pathway.[17] These pathways are critical for mediating the downstream effects of GH, such as promoting cell proliferation, differentiation, and survival (by inhibiting apoptosis), which collectively drive tissue and organ growth.[17]

The critical nature of the GH/IGF-1 axis is clinically illustrated by Laron Syndrome, a rare form of dwarfism caused by inactivating mutations in the GHR gene. Individuals with Laron Syndrome have high circulating levels of GH but are unable to produce IGF-1 in response. Consequently, they exhibit severe growth failure that is unresponsive to Somatotropin therapy but can be effectively treated with injections of recombinant IGF-1.[37]

3.3 Systemic Effects on Linear Growth and Bone Metabolism

The most prominent and therapeutically important effect of Somatotropin in the pediatric population is the stimulation of linear bone growth.[19] This is a complex process achieved through the coordinated direct actions of GH and the indirect actions of IGF-1 on the epiphyseal growth plates of long bones.[19]

At the growth plate, GH and IGF-1 act on chondrocytes (cartilage cells), stimulating their proliferation and differentiation, which leads to the expansion of the cartilaginous matrix that is subsequently mineralized into new bone.[17] They also stimulate osteoblasts, the cells responsible for bone formation.[17] In children with GHD, treatment with Somatotropin results in a dramatic acceleration of height velocity, often referred to as "catch-up growth," which is most pronounced during the first one to two years of therapy.[40] The efficacy of this treatment is highly dependent on consistent administration, as studies have shown that non-compliance with the daily injection schedule is a common cause of a suboptimal linear growth response.[42]

3.4 Metabolic Impact I: Anabolic Effects on Protein Metabolism

Somatotropin is a powerful anabolic hormone that promotes a state of positive protein balance throughout the body.[18] It enhances protein synthesis by increasing the cellular uptake of amino acids and directly stimulating the translational machinery.[44] Concurrently, it decreases protein catabolism and the oxidation of amino acids for energy.[23] This net anabolic effect is reflected clinically by positive nitrogen retention.[44]

The protein-sparing function of GH is particularly evident during periods of metabolic stress, such as fasting. The natural rise in endogenous GH levels during fasting is a key physiological adaptation to conserve lean body mass.[47] Studies have demonstrated that experimentally suppressing GH during a fast leads to a significant increase in urea-nitrogen excretion and muscle protein breakdown, confirming its critical role in preserving protein stores.[47]

3.5 Metabolic Impact II: Lipolytic Effects on Lipid Metabolism

One of the most immediate and direct metabolic actions of Somatotropin is the stimulation of lipolysis.[48] GH binds to its receptors on adipocytes (fat cells) and activates hormone-sensitive lipase, the key enzyme responsible for the breakdown of stored triglycerides into free fatty acids (FFAs) and glycerol.[16] This leads to a rapid increase in the circulating levels of these lipid substrates.[48]

The mobilization of fat from adipose stores serves a critical purpose: it provides an alternative energy source for tissues throughout the body. The increased availability of FFAs promotes a metabolic shift away from glucose and protein oxidation and toward lipid oxidation for energy production.[48] This effect is essential for supplying the substantial energy required for the anabolic processes of tissue growth and protein synthesis stimulated by GH.[51] In adults with GHD, who often present with increased central adiposity, long-term Somatotropin therapy leads to a beneficial shift in body composition, characterized by a reduction in fat mass (particularly visceral fat) and a corresponding increase in lean body mass.[19]

3.6 Metabolic Impact III: Diabetogenic Effects on Carbohydrate Metabolism

Somatotropin exerts complex and often counter-regulatory effects on carbohydrate metabolism, which are frequently described as "diabetogenic" or "anti-insulin".[23] It induces a state of insulin resistance in peripheral tissues, primarily skeletal muscle and adipose tissue, by impairing insulin's ability to stimulate glucose uptake.[18] Simultaneously, GH increases hepatic glucose production by stimulating both gluconeogenesis and glycogenolysis.[51]

The combined effect of reduced peripheral glucose uptake and increased hepatic glucose output can lead to an elevation in blood glucose levels (hyperglycemia) and impaired glucose tolerance, particularly at higher therapeutic doses.[54] This necessitates careful monitoring of glycemic status in all patients receiving Somatotropin, especially those with pre-existing diabetes or other risk factors.[25]

Paradoxically, while inducing insulin resistance, GH also stimulates the pancreatic beta-cells to increase insulin secretion.[23] This results in compensatory hyperinsulinemia, as the body attempts to overcome the state of insulin resistance.

These seemingly contradictory metabolic actions can be understood as part of an integrated physiological strategy of nutrient partitioning. By mobilizing energy from fat stores (lipolysis) and simultaneously making peripheral tissues less reliant on glucose (insulin resistance), Somatotropin ensures that the energy-intensive processes of protein synthesis and growth can proceed efficiently. This mechanism also serves to preserve glucose for tissues that are obligate glucose users, such as the brain. Thus, the diabetogenic effect is not merely an adverse reaction but an integral component of GH's overall metabolic program to prioritize anabolism and growth.

4. Clinical Pharmacology: Pharmacokinetics

The clinical use of Somatotropin is guided by its pharmacokinetic properties, which describe its absorption, distribution, metabolism, and elimination (ADME). These properties determine the dosing frequency and are influenced by patient-specific factors such as age and body composition.

4.1 Absorption, Distribution, Metabolism, and Elimination (ADME)

Absorption: Somatotropin is a polypeptide and would be degraded in the gastrointestinal tract if taken orally. Therefore, it is administered parenterally, typically via subcutaneous (SC) injection, although intramuscular (IM) administration is also possible.[57] Following SC administration, the hormone is well absorbed into the systemic circulation. Peak plasma concentrations (

Cmax​) are generally reached within 3 to 5 hours (Tmax​).[59] The absolute bioavailability of SC-administered Somatotropin is estimated to be approximately 63% to 70%, suggesting some local degradation at the injection site.[60]

Distribution: Once absorbed, Somatotropin distributes throughout the body, localizing primarily to highly perfused organs, with the liver and kidneys being major sites of uptake.[58] The apparent volume of distribution (

Vd​) is influenced by factors such as age and adiposity, with older individuals and those with higher fat mass exhibiting a larger Vd​.[61]

Metabolism: The primary sites of Somatotropin metabolism are the kidneys and, to a lesser extent, the liver.[58] The hormone is taken up by renal cells, where it is proteolytically cleaved into its constituent amino acids. These amino acids are then returned to the circulation for reuse by the body.[58]

Elimination: The elimination of Somatotropin from the circulation is relatively rapid. The mean clearance rate following intravenous infusion is approximately 2.3 mL/min/kg.[44] The circulating half-life (

t1/2​) is short, reported to be between 20 to 30 minutes after IV administration and approximately 2.5 to 4.3 hours after SC administration.[14]

A critical pharmacological concept is the distinction between Somatotropin's circulating half-life and its biological half-life. While the hormone itself is cleared from the blood within hours, its biological effects are sustained for much longer, with a biological half-life estimated at 9 to 17 hours.[14] This prolonged duration of action is a direct consequence of its mechanism. The injected GH acts as a trigger, stimulating the liver to produce IGF-1. IGF-1 is a much more stable molecule in circulation, and it is this sustained elevation of IGF-1 that mediates the long-term anabolic and growth-promoting effects. This principle explains why a once-daily injection is sufficient to promote a continuous process like growth and forms the rationale for the development of newer, long-acting formulations designed to provide even more stable IGF-1 levels.

4.2 Factors Influencing Pharmacokinetics: Age, Sex, and Body Composition

The pharmacokinetics of Somatotropin are not uniform across all patient populations and can be significantly influenced by individual characteristics.[61]

Age and Adiposity: Clinical studies have shown that both the metabolic clearance rate (MCR) and the apparent volume of distribution (Vd​) of GH increase with age and show a strong positive correlation with measures of body fat.[61] This suggests that adipose tissue may not be a passive storage depot but may play an active role in the clearance and distribution of the hormone, potentially contributing to the altered GH dynamics observed in aging and obesity.[61]

Sex and Estrogen Status: Sex-related differences in GH pharmacokinetics have also been observed. Endogenous GH secretion is generally higher in females than in males.[61] Clinically, it has been noted that women, particularly those receiving oral estrogen replacement therapy, may require higher doses of Somatotropin to achieve the same therapeutic effect as men.[55] This suggests that estrogen, especially after first-pass metabolism in the liver, may increase the clearance of Somatotropin or alter the sensitivity of target tissues.

5. Clinical Efficacy and Development

The therapeutic utility of Somatotropin has been rigorously established through decades of clinical trials and large-scale observational studies. The focus of clinical development has evolved from proving efficacy in its primary indication to expanding its use into other conditions and improving the treatment experience for patients.

5.1 Overview of Key Clinical Trials in Growth Hormone Deficiency (GHD)

Numerous completed Phase 2 and Phase 3 clinical trials have confirmed the efficacy and safety of Somatotropin for treating both pediatric and adult GHD.[65] In pediatric GHD, the primary endpoint of these trials is typically height velocity. Studies consistently demonstrate that Somatotropin therapy leads to a significant acceleration of growth, allowing children to achieve a final adult height closer to their genetic potential.[19]

Long-term evidence comes from large, post-marketing observational registries such as the Kabi International Growth Study (KIGS) and the National Cooperative Growth Study (NCGS). These studies, which have followed tens of thousands of children on rhGH therapy, have shown that treated children can achieve mean height improvements of +1.6 to +2.5 standard deviation scores (SDS) from their baseline, often bringing them within the normal range for their families.[19]

In adults with GHD, clinical trials have focused on metabolic and quality-of-life endpoints. Studies have investigated Somatotropin's effects on improving body composition (increasing lean mass, decreasing fat mass), enhancing bone mineral density, reducing cardiovascular risk factors, and improving insulin sensitivity.[65]

The clinical trial landscape also reflects a clear evolution in therapeutic priorities. The primary challenge of daily injections, which can lead to poor compliance and suboptimal outcomes, has driven the development of patient-centric innovations. This is evidenced by trials evaluating the efficacy of needle-free delivery devices (e.g., Zomajet®) and, more significantly, the development of long-acting formulations designed for once-weekly administration.[65] Trials comparing these novel weekly formulations, such as TransCon hGH (lonapegsomatropin) and somatrogon, against daily Somatotropin have been pivotal in establishing their non-inferiority and paving the way for their regulatory approval.[67]

5.2 Evidence in Other Pediatric and Adult Conditions

With a secure and plentiful supply of rhGH, clinical research expanded beyond GHD to explore its therapeutic potential in other conditions characterized by short stature or metabolic dysregulation. Completed clinical trials have provided the evidence base for regulatory approval in several non-GHD pediatric conditions, including Turner syndrome, Noonan syndrome, Prader-Willi syndrome, and for children born small for gestational age (SGA).[44]

In adult medicine, trials have successfully demonstrated Somatotropin's efficacy in treating the wasting syndrome (cachexia) associated with HIV/AIDS and in managing short bowel syndrome.[44] Exploratory clinical trials have also been conducted to assess its potential benefits in conditions such as chronic heart failure and fibromyalgia, often in combination with other therapeutic agents.[66] The development of novel long-acting growth hormones, such as Eftansomatropin alfa and Albusomatropin, has been evaluated in clinical trials for both adult and pediatric GHD, representing the next generation of GH replacement therapy.[66] This broad research portfolio illustrates a mature drug development pathway, moving from a single primary indication to a wider range of therapeutic applications and continuous innovation in drug delivery and formulation.

6. Regulatory Landscape and Therapeutic Applications

Somatotropin is a globally approved medication with a well-defined set of indications in both pediatric and adult populations. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have authorized its use for various conditions related to growth failure and metabolic dysfunction. It is marketed under numerous brand names, including several biosimilar and long-acting formulations.

6.1 FDA and EMA Approved Indications in Pediatric Populations

In pediatric medicine, Somatotropin is the standard of care for growth failure resulting from a range of underlying conditions. The FDA and EMA share many approved indications, though minor differences may exist.

FDA-Approved Pediatric Indications:

• Growth Hormone Deficiency (GHD): For children with growth failure due to inadequate secretion of endogenous growth hormone.[44]
• Turner Syndrome: For short stature associated with this genetic condition in girls.[44]
• Prader-Willi Syndrome (PWS): For growth failure associated with this genetic disorder.[44]
• Small for Gestational Age (SGA): For short stature in children born SGA who fail to demonstrate catch-up growth by age 2 to 4 years.[72]
• Idiopathic Short Stature (ISS): For non-GHD short stature defined by a height SDS ≤-2.25 and a growth rate unlikely to permit attainment of normal adult height.[72]
• Noonan Syndrome: For short stature associated with this genetic condition.[71]
• SHOX Gene Deficiency: For short stature resulting from a deficiency of the Short Stature Homeobox-containing gene.[72]
• Chronic Kidney Disease (CKD): For growth failure in children with CKD up to the time of renal transplantation.[19]

EMA-Approved Pediatric Indications:

The EMA's approved indications are largely similar, covering GHD, Turner Syndrome, PWS, SGA, and chronic renal insufficiency.53 The EMA has been a leader in the regulation of biosimilar products, approving the first biosimilar Somatropin (Omnitrope®) in 2006.77

6.2 FDA and EMA Approved Indications in Adult Populations

In adults, Somatotropin is primarily used as a replacement therapy for GHD and for specific metabolic conditions.

FDA-Approved Adult Indications:

• Adult GHD: For replacement of endogenous GH in adults with either adult-onset GHD (resulting from pituitary disease, surgery, trauma, or radiation) or childhood-onset GHD.[44]
• HIV-Associated Wasting (Cachexia): To increase lean body mass and body weight and improve physical endurance in patients with HIV-associated wasting (marketed as Serostim®).[44]
• Short Bowel Syndrome (SBS): For patients dependent on parenteral nutrition (marketed as Zorbtive®).[44]

The EMA has also approved Somatotropin for adult GHD replacement therapy.[53]

A summary of the major approved indications across both regulatory bodies is provided in Table 2.

Table 2: Summary of Major FDA and EMA Approved Indications for Somatotropin

Indication	Patient Population	FDA Approval	EMA Approval	Source(s)
Growth Hormone Deficiency (GHD)	Pediatric & Adult	Yes	Yes	44
Turner Syndrome	Pediatric	Yes	Yes	44
Prader-Willi Syndrome (PWS)	Pediatric	Yes	Yes	44
Small for Gestational Age (SGA)	Pediatric	Yes	Yes	73
Chronic Kidney Disease (CKD)	Pediatric	Yes	Yes	44
Idiopathic Short Stature (ISS)	Pediatric	Yes	No	73
Noonan Syndrome	Pediatric	Yes	No	71
SHOX Deficiency	Pediatric	Yes	No	72
HIV-Associated Wasting	Adult	Yes	No	44
Short Bowel Syndrome (SBS)	Adult	Yes	No	44

6.3 Global Commercial Formulations and Brand Names

Somatotropin is a blockbuster drug class marketed globally by several pharmaceutical companies under various brand names. The proliferation of products includes originator brands, biosimilars, and novel long-acting formulations. This diversity offers choice but also requires careful differentiation by clinicians. A summary of major commercial formulations is presented in Table 3.

Table 3: Major Commercial Formulations of Somatotropin

Brand Name	Manufacturer	Key Feature/Formulation	Unique Approved Indication(s)	Source(s)
Genotropin®	Pfizer	Daily injection; available in pen devices	GHD, PWS, SGA, TS, ISS	79
Humatrope®	Eli Lilly	Daily injection; available in pen devices	GHD, TS, ISS, SHOX, SGA	14
Norditropin®	Novo Nordisk	Daily injection; prefilled pen device	GHD, Noonan, TS, SGA, ISS, PWS	71
Omnitrope®	Sandoz	Daily injection; first biosimilar in EU/US	GHD, PWS, SGA, TS, ISS	75
Saizen®	Merck Serono	Daily injection; reconstitution systems	GHD, TS, SGA (EU)	76
Serostim®	Merck Serono	Daily injection; high-dose formulation	HIV-associated Wasting	78
Zorbtive®	Merck Serono	Daily injection	Short Bowel Syndrome	44
Skytrofa®	Ascendis Pharma	Once-weekly long-acting prodrug	Pediatric GHD	86
Sogroya®	Novo Nordisk	Once-weekly long-acting protein	Adult GHD	86
Ngenla™	Pfizer/OPKO	Once-weekly long-acting protein	Pediatric GHD	86

7. Safety, Tolerability, and Risk Management

The safety profile of Somatotropin has been extensively studied and is well-understood. While generally considered safe and effective for its approved indications, its use is associated with a range of potential adverse effects and requires careful patient selection and monitoring to mitigate risks. Notably, the most severe risks are concentrated in specific, identifiable subpopulations, and the drug class does not carry a Black Box Warning in the United States.[44]

7.1 Common and Serious Adverse Events

Adverse reactions to Somatotropin are often related to its physiological effects on fluid balance, metabolism, and growth. A systematic overview of adverse reactions is presented in Table 4.

Common Adverse Events:

The most frequently reported adverse effects include:

• Injection Site Reactions: Pain, erythema (redness), hematoma (bruising), rash, and lipoatrophy (localized loss of fat tissue) at the injection site are common. Rotating injection sites is recommended to minimize this risk.[91]
• Fluid Retention: Manifesting as peripheral edema (swelling of hands and feet), arthralgia (joint pain), and myalgia (muscle pain). These effects are more common in adults, are typically dose-dependent, and often resolve with dose reduction.[25]
• Headache: A commonly reported side effect in both pediatric and adult populations.[91]

Serious Adverse Events:

While less common, several serious adverse events warrant clinical vigilance:

• Intracranial Hypertension (IH): A rare but serious condition characterized by increased pressure within the skull. It typically presents within the first eight weeks of treatment with symptoms of severe headache, nausea, vomiting, and visual disturbances (papilledema). IH is usually reversible upon discontinuation or dose reduction of the therapy.[19]
• Pancreatitis: Rare cases of inflammation of the pancreas have been reported. Pancreatitis should be considered in any patient, particularly a child, who develops persistent, severe abdominal pain during treatment.[91]
• Slipped Capital Femoral Epiphysis (SCFE): In pediatric patients, the rapid growth spurred by Somatotropin can increase mechanical stress on the hip's growth plate, raising the risk of SCFE. Any child who develops a limp or complains of hip or knee pain should be promptly evaluated.[19]
• Progression of Pre-existing Scoliosis: Rapid linear growth can lead to the worsening of pre-existing curvature of the spine. Patients with scoliosis should be monitored during therapy.[94]
• Neoplasms: In survivors of childhood cancer who were treated with cranial radiation, subsequent treatment with Somatotropin has been associated with an increased risk of a second neoplasm, most commonly intracranial tumors like meningiomas.[94]

Table 4: Summary of Adverse Reactions by System Organ Class

System Organ Class	Frequency	Adverse Reaction	Source(s)
Endocrine Disorders	Common	Hypothyroidism, Hyperglycemia, Insulin Resistance	58
Nervous System Disorders	Common	Headache, Paresthesia	58
	Rare	Intracranial Hypertension	58
Musculoskeletal & Connective Tissue	Common	Arthralgia, Myalgia, Musculoskeletal stiffness	58
	Uncommon	Slipped Capital Femoral Epiphysis	92
Gastrointestinal Disorders	Rare	Pancreatitis	58
General Disorders & Admin. Site	Very Common	Peripheral Edema (adults)	92
	Common	Injection site reactions (pain, lipoatrophy), Fatigue	58
Immune System Disorders	Rare	Hypersensitivity reactions (anaphylaxis, angioedema)	58

7.2 Contraindications and High-Risk Populations

The use of Somatotropin is strictly contraindicated in several clinical situations where the risk of serious harm outweighs the potential benefit.

• Active Malignancy: Somatotropin promotes tissue growth and is therefore contraindicated in patients with any active cancer. Any pre-existing tumor must be inactive and treatment complete before initiating therapy.[94]
• Acute Critical Illness: Two large placebo-controlled trials demonstrated a significant increase in mortality in non-GHD adult patients treated with pharmacologic doses of Somatropin during acute critical illness following complications from open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure. Consequently, its use is contraindicated in this setting.[71]
• Diabetic Retinopathy: Contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy due to the potential for worsening the condition.[94]
• Closed Epiphyses: Somatotropin should not be used for the purpose of growth promotion in pediatric patients whose epiphyseal growth plates have fused.[99]
• Hypersensitivity: Known hypersensitivity to Somatropin or any of its excipients (e.g., m-cresol, a preservative in some formulations) is a contraindication.[95]
• Prader-Willi Syndrome (PWS): This patient group carries a specific and serious risk. There have been reports of sudden death in children with PWS treated with Somatropin who were also severely obese, had a history of upper airway obstruction or sleep apnea, or had a severe respiratory impairment. Therefore, Somatropin is contraindicated in PWS patients with these risk factors.[80]

7.3 Warnings, Precautions, and Monitoring Requirements

Beyond absolute contraindications, several conditions require careful consideration and vigilant monitoring during Somatotropin therapy.

• Glucose Intolerance: Due to its anti-insulin effects, Somatropin can unmask latent glucose intolerance or worsen pre-existing diabetes mellitus. Periodic monitoring of blood glucose levels is recommended for all patients, and doses of antidiabetic medications may need to be adjusted.[76]
• Hypothyroidism: Somatropin therapy can unmask or worsen central (secondary) hypothyroidism. Since adequate thyroid hormone levels are necessary for an optimal growth response, thyroid function should be monitored periodically and thyroid hormone replacement initiated or adjusted as needed.[58]
• Hypoadrenalism: By inhibiting the enzyme 11βHSD-1, Somatropin can reduce the conversion of cortisone to active cortisol, potentially unmasking central hypoadrenalism. Patients already receiving glucocorticoid replacement may require an increase in their maintenance or stress doses.[63]
• Routine Monitoring: Standard clinical practice includes regular monitoring of height and weight in children, serum IGF-1 levels to guide dose titration, and periodic assessment of glucose and thyroid function.[58] A fundoscopic examination to screen for papilledema is recommended at the start of therapy and periodically thereafter to detect IH.[95]

8. Clinically Significant Drug Interactions

Somatotropin's role as a major endocrine and metabolic hormone leads to several clinically significant drug-drug interactions. These interactions are largely predictable consequences of its physiological functions and require careful management in patients on polypharmacy.

8.1 Interaction with Glucocorticoids

The interaction between Somatotropin and glucocorticoids is complex and bidirectional.

• Pharmacodynamic Antagonism: Supraphysiologic doses of glucocorticoids can interfere with the GH/IGF-1 axis and directly antagonize the growth-promoting effects of Somatropin. In children receiving glucocorticoids for conditions like asthma or as part of an immunosuppressive regimen, this can lead to growth attenuation. Therefore, glucocorticoid doses should be carefully managed and minimized to avoid inhibiting the therapeutic effect of Somatotropin on growth.[55]
• Metabolic Interaction: Somatropin inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1). This enzyme is crucial for the intracellular conversion of inactive cortisone and prednisone into their active metabolite, cortisol. By inhibiting this enzyme, Somatropin can reduce local and systemic cortisol levels. This can unmask previously undiagnosed central (secondary) hypoadrenalism, necessitating the initiation of glucocorticoid replacement. In patients already on glucocorticoid therapy, particularly with cortisone or prednisone, an increase in their maintenance or stress doses may be required to compensate for the reduced activation.[55]

8.2 Interaction with Insulin and Antidiabetic Agents

As detailed in the pharmacodynamics section, Somatotropin induces a state of insulin resistance, leading to diabetogenic effects.[56] This has direct implications for patients with diabetes mellitus.

• Decreased Efficacy: Somatropin can decrease the hypoglycemic efficacy of insulin and other oral or injectable antidiabetic agents (e.g., metformin, sulfonylureas, GLP-1 agonists).[44]
• Dose Adjustment: Consequently, patients with diabetes who initiate Somatotropin therapy often require an increase in the dosage of their antidiabetic medications to maintain adequate glycemic control. Close monitoring of blood glucose is essential, especially during the initial phase of treatment and after any dose adjustments of Somatotropin.[55]

8.3 Interaction with Oral Estrogens

Clinical evidence indicates that women receiving oral estrogen replacement therapy may require larger doses of Somatropin to achieve the same therapeutic IGF-1 levels and clinical response compared to men or women not on oral estrogen.[63] This interaction is thought to be due to the first-pass hepatic metabolism of oral estrogen, which may increase GH clearance or induce a state of relative GH resistance in the liver, thereby reducing IGF-1 production. Transdermal estrogen administration does not appear to have the same effect.

8.4 Influence on Cytochrome P450 (CYP450) Metabolized Drugs

Somatotropin has been shown to influence the activity of the hepatic cytochrome P450 enzyme system, which is responsible for the metabolism of a vast number of drugs.

• Enzyme Induction: Limited published data indicate that Somatotropin treatment increases the clearance of antipyrine, a probe for overall CYP450 activity. Specifically, it appears to induce the activity of CYP3A4 and CYP1A2 enzymes.[55]
• Clinical Implications: This induction may alter the clearance and decrease the plasma concentrations of various compounds metabolized by these enzymes, including corticosteroids, sex steroids (e.g., testosterone), anticonvulsants (e.g., carbamazepine), and immunosuppressants (e.g., cyclosporine).[63] Therefore, careful monitoring is advisable when Somatropin is co-administered with CYP450 substrates, particularly those with a narrow therapeutic index. Dose adjustments of the concomitant medication may be necessary.[55]

A summary of these key interactions and their management is provided in Table 5.

Table 5: Clinically Significant Drug Interactions and Management Recommendations

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Glucocorticoids	1. Pharmacodynamic antagonism of growth effects. 2. Somatropin inhibits 11βHSD-1, reducing cortisol activation.	1. Attenuation of linear growth in children. 2. May unmask central hypoadrenalism or require increased glucocorticoid dose.	1. Use lowest effective glucocorticoid dose; monitor growth. 2. Monitor for signs of adrenal insufficiency; adjust glucocorticoid dose as needed.	55
Insulin / Antidiabetic Agents	Pharmacodynamic antagonism; Somatropin induces insulin resistance.	Decreased efficacy of hypoglycemic agents, potentially leading to hyperglycemia.	Closely monitor blood glucose. Increase dose of insulin or other antidiabetic agents as needed.	55
Oral Estrogens	Increased first-pass hepatic effect of estrogen may increase Somatropin clearance or induce hepatic GH resistance.	Reduced IGF-1 response to Somatropin, potentially decreasing therapeutic efficacy.	Patients on oral estrogen may require higher doses of Somatropin. Monitor IGF-1 levels and clinical response.	63
CYP450 Substrates (e.g., CYP3A4, CYP1A2)	Somatropin induces hepatic CYP450 enzyme activity.	Increased clearance and potentially decreased plasma concentrations and efficacy of co-administered drugs.	Monitor clinical effect and/or plasma levels of concomitant CYP-metabolized drugs, especially those with a narrow therapeutic index. Dose adjustment may be necessary.	55

9. Biotechnology and Manufacturing

Modern Somatotropin is a product of sophisticated biotechnology, manufactured using recombinant DNA (rDNA) techniques that ensure a high-purity, consistent, and safe supply of the hormone. This process has entirely replaced the previous, hazardous method of extraction from cadaveric pituitary glands.

9.1 The Recombinant DNA Production Process

The manufacturing process for Somatotropin begins with the human gene that codes for the 191-amino acid protein.[115]

1. Gene Cloning and Vector Construction: The DNA sequence for hGH is isolated, often by reverse transcribing the messenger RNA (mRNA) from pituitary tissue to create complementary DNA (cDNA).[117] This gene is then inserted into a small, circular piece of DNA called a plasmid vector. This vector is engineered to contain regulatory elements, such as a promoter (e.g., trc promoter), that will drive the expression of the hGH gene in the host cell.[116]
2. Host Cell Transformation: The recombinant plasmid is introduced into a host organism. The most widely used host for Somatropin production is the bacterium Escherichia coli due to its rapid growth and high protein yield.[117] However, other expression systems, including yeast ( Saccharomyces cerevisiae), mammalian cell lines (e.g., mouse C127), and insect cells, have also been utilized.[39]
3. Fermentation: The transformed host cells are cultured in large, industrial-scale bioreactors or fermenters.[115] They are grown in a carefully controlled environment with an optimized nutrient medium, which may include specific trace elements like manganese and zinc to improve protein folding and reduce the formation of aggregates.[118] When the cell culture reaches a high density, an inducing agent (e.g., Isopropyl β-D-1-thiogalactopyranoside, IPTG) is added to switch on the promoter and initiate high-level production of the recombinant hGH protein.[116]

9.2 Purification, Formulation, and Quality Control

The downstream process of recovering and purifying the active hormone from the host cells is a critical and complex stage of manufacturing.

1. Harvesting and Lysis: After fermentation, the cells are harvested and broken open (lysed) to release the cellular contents, including the recombinant protein.[116]
2. Inclusion Body Processing: When overexpressed at high levels in the cytoplasm of E. coli, Somatropin often accumulates in dense, insoluble, and non-functional aggregates known as inclusion bodies.[118] This presents a significant manufacturing challenge. The inclusion bodies must first be isolated from other cellular debris. They are then solubilized using harsh chemical denaturants (chaotropic agents) or extreme pH (e.g., an alkaline pH of 10-12.5) to unfold the misfolded protein.[118] Following solubilization, the protein must be carefully refolded into its correct three-dimensional, biologically active conformation—a delicate and often yield-limiting step.[118]
3. Purification: The refolded, soluble Somatotropin is then subjected to a series of purification steps to separate it from host cell proteins and other impurities. Multi-step column chromatography is the standard method. Affinity chromatography is a powerful technique often employed, especially if the protein has been engineered with a purification tag (e.g., a polyhistidine tag), which allows it to bind specifically to a column matrix (e.g., a nickel-charged resin).[116]
4. Quality Control and Formulation: The final purified protein undergoes extensive analytical characterization to ensure its identity, purity (typically >95%), potency, and safety. A battery of tests, including high-performance liquid chromatography (HPLC), electrophoresis, and bioassays, are used to confirm the correct structure and to detect and quantify any impurities, aggregates, or structural variants.[117] The highly purified Somatotropin is then formulated into a stable final product, either as a lyophilized (freeze-dried) powder requiring reconstitution or as a ready-to-use liquid solution, often containing excipients like glycine, mannitol, and preservatives to maintain stability.[121]

The manufacturing process, particularly the trade-off between the high-yield fermentation in E. coli and the complex downstream challenge of refolding from inclusion bodies, represents a major focus of process optimization and a critical determinant of the final product's quality, consistency, and cost.

10. Conclusion and Future Perspectives

10.1 Summary of Somatotropin's Therapeutic Role

Somatotropin has firmly established its place as an indispensable therapeutic agent in clinical endocrinology. Its journey from a high-risk, scarce biologic to a safe, mass-produced biotech drug is a testament to the power of scientific innovation in overcoming formidable clinical challenges. Through its well-characterized mechanism of action on the GH/IGF-1 axis, Somatotropin effectively stimulates linear growth in children with a variety of growth disorders and provides crucial metabolic benefits to adults with growth hormone deficiency. Its pleiotropic effects—promoting protein anabolism, mobilizing fat stores, and modulating glucose homeostasis—underscore its role as a master regulator of metabolism. With a robust evidence base from decades of clinical use and a manageable safety profile under vigilant clinical supervision, Somatotropin remains the standard of care for its approved indications.

10.2 Emerging Developments: Long-Acting Formulations and Future Research

The most significant evolution in Somatotropin therapy is the recent development and regulatory approval of long-acting formulations designed for once-weekly administration. Products such as Sogroya® (somapacitan), Skytrofa® (lonapegsomatropin), and Ngenla™ (somatrogon) represent a paradigm shift in treatment.[86] The primary driver for this innovation is the long-standing clinical challenge of adherence to a therapeutic regimen that requires daily subcutaneous injections, often for many years. Poor compliance is a well-documented cause of suboptimal growth outcomes in children.[42]

Clinical trials have demonstrated that these once-weekly agents are non-inferior to daily Somatropin in terms of efficacy (e.g., annual height velocity) and have a comparable safety profile.[89] Furthermore, studies have shown that a weekly regimen significantly reduces the treatment burden for patients and their families.[125] This focus on the patient experience marks a maturation of the therapeutic field, moving beyond simply establishing efficacy to optimizing real-world effectiveness and quality of life.

Future research will likely concentrate on several key areas: generating long-term safety and efficacy data for these newer formulations, expanding their approved indications to match those of daily Somatropin, and continuing to explore the potential therapeutic role of GH modulation in other metabolic diseases, cachectic states, and age-related conditions. The ongoing evolution of Somatropin therapy ensures that it will remain a vital and improving tool in the physician's armamentarium for years to come.

Works cited

1. History of growth hormone therapy - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3183530/
2. Human growth hormone invented | EBSCO Research Starters, accessed July 18, 2025, https://www.ebsco.com/research-starters/history/human-growth-hormone-invented
3. Growth hormone - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Growth_hormone
4. www.ebsco.com, accessed July 18, 2025, https://www.ebsco.com/research-starters/history/human-growth-hormone-invented#:~:text=By%20the%201960s%2C%20the%20unique,HGH%2C%20resulting%20in%20measurable%20growth.
5. Prescribing growth hormone in pediatrics: The collision of history and medical ethics, accessed July 18, 2025, https://blogs.bmj.com/medical-ethics/2022/10/14/prescribing-growth-hormone-in-pediatrics-the-collision-of-history-and-medical-ethics/
6. History of growth hormone therapy - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/22081428/
7. The big story behind synthetic human growth hormone | National ..., accessed July 18, 2025, https://americanhistory.si.edu/blog/2012/10/human-growth-hormone.html
8. Cadaveric human growth hormone | National Prion Clinic - UCL ..., accessed July 18, 2025, https://www.ucl.ac.uk/national-prion-clinic/cadaveric-human-growth-hormone
9. Woman dies of Creutzfeldt-Jakob almost 50 years after taking prion-contaminated growth hormone | CIDRAP, accessed July 18, 2025, https://www.cidrap.umn.edu/misc-emerging-topics/woman-dies-creutzfeldt-jakob-almost-50-years-after-taking-prion-contaminated
10. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years - Oxford Academic, accessed July 18, 2025, https://academic.oup.com/brain/article/138/11/3386/330626
11. National Hormone & Pituitary Program (NHPP): Information for People Treated with Pituitary Human Growth Hormone - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), accessed July 18, 2025, https://www.niddk.nih.gov/health-information/endocrine-diseases/national-hormone-pituitary-program
12. Study Of Growth Hormone Treatment And Creutzfeldt-Jakob Disease Underscores Need For Prevention Of Adrenal Crises | ScienceDaily, accessed July 18, 2025, https://www.sciencedaily.com/releases/2004/04/040407083216.htm
13. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/9255218/
14. Human growth hormone (trade names: Genotropin®, Humatrope®, Norditropin®, Nutropin®, Saizen®, Serostim®), accessed July 18, 2025, https://www.deadiversion.usdoj.gov/drug_chem_info/hgh.pdf
15. FDA Approves Genentech's Drug To Treat Children's Growth Disorder - BioSpace, accessed July 18, 2025, https://www.biospace.com/fda-approves-genentech-s-drug-to-treat-children-s-growth-disorder
16. Somatotropin | 12629-01-5 - ChemicalBook, accessed July 18, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1151396.htm
17. Physiology, Growth Hormone - StatPearls - NCBI Bookshelf, accessed July 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482141/
18. Types, Regulation & Growth Hormone Function - BYJU'S, accessed July 18, 2025, https://byjus.com/biology/growth-hormone/
19. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3262362/
20. Somatotropin Long Isoform (human, recombinant) - Cayman Chemical, accessed July 18, 2025, https://www.caymanchem.com/product/32090/somatotropin-long-isoform-(human%2C-recombinant)
21. CAS 12629-01-5 Growth hormone,human - Alfa Chemistry, accessed July 18, 2025, https://www.alfa-chemistry.com/growth-hormone-human-cas-12629-01-5-item-289905.htm
22. Growth Hormone, Human Pituitary, Iodination Grade CAS 12629-01-5 | 869008 - Merck, accessed July 18, 2025, https://www.merckmillipore.com/INTL/en/product/Growth-Hormone-Human-Pituitary-Iodination-Grade,EMD_BIO-869008
23. Growth Hormone (Somatotropin), accessed July 18, 2025, https://vivo.colostate.edu/hbooks/pathphys/endocrine/hypopit/gh.html
24. Somatotropin Penetration Testing from Formulations Applied Topically to the Skin - MDPI, accessed July 18, 2025, https://www.mdpi.com/2076-3417/13/4/2588
25. HGH (Human Growth Hormone): What It Is, Benefits & Side Effects - Cleveland Clinic, accessed July 18, 2025, https://my.clevelandclinic.org/health/articles/23309-human-growth-hormone-hgh
26. Growth hormone receptor: structure and signal transduction - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/8548048/
27. Growth hormone receptor - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Growth_hormone_receptor
28. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects - Frontiers, accessed July 18, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00035/full
29. The Role of HGH in Signal Transduction - Number Analytics, accessed July 18, 2025, https://www.numberanalytics.com/blog/hgh-signal-transduction-pathways
30. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects - PMC - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5816795/
31. Growth hormone-mediated JAK/STAT signal transduction. GH activates... - ResearchGate, accessed July 18, 2025, https://www.researchgate.net/figure/Growth-hormone-mediated-JAK-STAT-signal-transduction-GH-activates-several-signaling_fig2_6163824
32. The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10573540/
33. Growth hormone-stimulated insulin-like growth factor-1 expression in rainbow trout (Oncorhynchus mykiss) hepatocytes is mediated by ERK, PI3K-AKT, and JAK-STAT - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/21490369/
34. Insulin-like growth factor - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Insulin-like_growth_factor
35. IGF-1 Signaling - GeneGlobe - QIAGEN, accessed July 18, 2025, https://geneglobe.qiagen.com/us/knowledge/pathways/igf-1-signaling
36. IGF-1 Signaling Pathway - Creative Diagnostics, accessed July 18, 2025, https://www.creative-diagnostics.com/igf-1-signaling-pathway.htm
37. Laron syndrome - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Laron_syndrome
38. Saizen [somatropin (rDNA origin) for injection] For subcutaneous or intramuscular injection DESCRIPTION Saizen® [somatropin (rD - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019764s034lbl.pdf
39. Saizen [somatropin (rDNA origin) for injection] For subcutaneous or intramuscular injection DESCRIPTION Saizen® [somatropin (rD - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019764s035lbl.pdf
40. Pediatric Growth Hormone Deficiency | HGF, accessed July 18, 2025, https://www.hgfound.org/pediatric-growth-hormone-deficiency
41. The Use of Growth Hormone Therapy in Children - AAFP, accessed July 18, 2025, https://www.aafp.org/pubs/afp/issues/2000/0301/p1510.html
42. Non-Compliance with Growth Hormone Treatment in Children Is Common and Impairs Linear Growth | PLOS One - Our journal portfolio - PLOS, accessed July 18, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016223
43. Growth Hormone Effects on Protein Metabolism - Mayo Clinic, accessed July 18, 2025, https://mayoclinic.elsevierpure.com/en/publications/growth-hormone-effects-on-protein-metabolism
44. Somatotropin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00052
45. Somatotropin increases protein balance independent of insulin's, accessed July 18, 2025, https://journals.physiology.org/doi/pdf/10.1152/ajpendo.2000.279.1.E1
46. Growth Hormone Effects - News-Medical.net, accessed July 18, 2025, https://www.news-medical.net/health/Growth-Hormone-Effects.aspx
47. The Protein-Retaining Effects of Growth Hormone During Fasting Involve Inhibition of Muscle-Protein Breakdown - American Diabetes Association, accessed July 18, 2025, https://diabetesjournals.org/diabetes/article/50/1/96/10905/The-Protein-Retaining-Effects-of-Growth-Hormone
48. Effects of growth hormone on lipid metabolism in humans - Paulo Gentil, accessed July 18, 2025, https://paulogentil.com/pdf/Effects%20of%20growth%20hormone%20on%20lipid%20metabolism%20in%20humans.pdf
49. Effects of growth hormone on lipid metabolism in humans - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/12914720/
50. Biological Effects of Growth Hormone on Carbohydrate and Lipid ..., accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2815161/
51. Why would growth hormone (somatotropin) cause both lipid AND glucose release?, accessed July 18, 2025, https://biology.stackexchange.com/questions/40393/why-would-growth-hormone-somatotropin-cause-both-lipid-and-glucose-release
52. Effect of growth hormone on lipid metabolism-basic and clinical aspects - ResearchGate, accessed July 18, 2025, https://www.researchgate.net/publication/281786812_Effect_of_growth_hormone_on_lipid_metabolism-basic_and_clinical_aspects
53. EMA Gives Nod to New Growth Hormone, Somatropin Biopartners - Medscape, accessed July 18, 2025, https://www.medscape.com/viewarticle/805068
54. Glucose Metabolism in Children With Growth Hormone Deficiency - Frontiers, accessed July 18, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00321/full
55. Genotropin, Humatrope (somatropin) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 18, 2025, https://reference.medscape.com/drug/genotropin-somatropin-342860
56. go.drugbank.com, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00052#:~:text=The%20diabetogenic%20effect%20of%20larger,insulin%20resistance%20and%20glucose%20intolerance.
57. Somatropin, mammalian derived (injection route, subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/drugs-supplements/somatropin-mammalian-derived-injection-route-subcutaneous-route/description/drg-20071668
58. Somatropin (Recombinant) (Omnitrope) - Omnitrope | Davis's Drug Guide - Nursing Central, accessed July 18, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109840/all/somatropin__recombinant___Omnitrope_
59. Pharmacokinetics and Pharmacodynamics of Growth Hormone-Releasing Peptide-2: A Phase I Study in Children1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed July 18, 2025, https://academic.oup.com/jcem/article/83/4/1168/2865268
60. The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2014216/
61. Metabolic Effects and Pharmacokinetics of a Growth Hormone Pulse ..., accessed July 18, 2025, https://academic.oup.com/jcem/article/82/11/3612/2865955
62. Somatropin Health Professional Drug Record | NIH - Clinical Info HIV.gov, accessed July 18, 2025, https://clinicalinfo.hiv.gov/en/drugs/somatropin/health-professional
63. GENOTROPIN® (somatropin) Drug Interactions | Pfizer Medical - US, accessed July 18, 2025, https://www.pfizermedical.com/genotropin/drug-interactions
64. Saizen Prescribing Information - EMD Serono, accessed July 18, 2025, https://www.emdserono.com/us-en/pi/saizen-ce-pi.pdf
65. Growth Hormone-Deficiency Completed Phase Trials for Somatotropin (DB00052), accessed July 18, 2025, https://go.drugbank.com/indications/DBCOND0069168/clinical_trials/DB00052?phase=&status=completed
66. Growth Hormone Deficiency Completed Phase 2 Trials for Somatotropin (DB00052), accessed July 18, 2025, https://go.drugbank.com/indications/DBCOND0029025/clinical_trials/DB00052?phase=2&status=completed
67. Somatotropin Completed Phase 3 Trials for Pituitary gland disorder / Endocrine System Diseases / childhood onset Growth Hormone Deficiency / Hormone Deficiency Treatment - DrugBank, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00052/clinical_trials?conditions=DBCOND0020400%2CDBCOND0031899%2CDBCOND0053256%2CDBCOND0170135&phase=3&purpose=treatment&status=completed
68. Somatotropin Completed Phase 3 Trials for hGH (Human Growth Hormone) / Pituitary gland disorder / Hormones / Endocrine System Diseases / childhood onset Growth Hormone Deficiency Treatment - DrugBank, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00052/clinical_trials?conditions=DBCOND0020400%2CDBCOND0031899%2CDBCOND0081188%2CDBCOND0034949%2CDBCOND0033121&phase=3&purpose=treatment&status=completed
69. Somatotropin Completed Phase 2 Trials for Human Growth Hormone Deficiency Treatment, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00052/clinical_trials?conditions=DBCOND0051106&phase=2&purpose=treatment&status=completed
70. Somatotropin Completed Phase 2 Trials for childhood onset Growth Hormone Deficiency Treatment | DrugBank Online, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00052/clinical_trials?conditions=DBCOND0020400&phase=2&purpose=treatment&status=completed
71. Norditropin: Package Insert / Prescribing Information - Drugs.com, accessed July 18, 2025, https://www.drugs.com/pro/norditropin.html
72. Somatropin Information - FDA, accessed July 18, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/somatropin-information
73. GENOTROPIN® (somatropin) Indications and Usage | Pfizer ..., accessed July 18, 2025, https://www.pfizermedical.com/genotropin/indications-usage
74. Somatropin - referral | European Medicines Agency (EMA), accessed July 18, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/somatropin
75. Omnitrope | European Medicines Agency (EMA), accessed July 18, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope
76. Saizen (somatropin) Indication, Dosing and Drug Details, accessed July 18, 2025, https://hcp.merckgroup.com/sg-en/endocrinology/saizen/saizen-details/about-saizen.html
77. Ten years of biosimilar recombinant human growth hormone in ..., accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5439961/
78. Serostim 1870-A SGM P2022 - Specialty Pharmacy Clinical Policy ..., accessed July 18, 2025, https://www.aetna.com/products/rxnonmedicare/data/2023/Serostim_1870-A_SGM_P2022.html
79. GENOTROPIN MiniQuick®, accessed July 18, 2025, https://www.genotropin.com/images/sites/default/files/PP-GEN-USA-1127_MiniQuick_Instructional_Bro_DIGITAL_22-GEN-0169_DR.pdf
80. Genotropin: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed July 18, 2025, https://www.drugs.com/genotropin.html
81. Humatrope: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed July 18, 2025, https://www.drugs.com/humatrope.html
82. Growth Hormone Therapy | Norditropin® (somatropin) 10 mg injection, accessed July 18, 2025, https://www.norditropin.com/
83. Omnitrope - indications in children and adults, accessed July 18, 2025, https://www.omnitrope.com/pro/why-omnitrope/indications/
84. Saizen Uses, Side Effects & Warnings - Drugs.com, accessed July 18, 2025, https://www.drugs.com/mtm/saizen.html
85. List of Growth hormones (human growth hormone) - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-class/growth-hormones.html
86. FDA Approves Weekly Sub-q hGH - Ngenla - Anton Health, accessed July 18, 2025, https://antonhealth.com/fda-approves-weekly-sub-q-hgh-ngenla/
87. FDA Approves First Once-Weekly Growth Hormone for Children - Medscape, accessed July 18, 2025, https://www.medscape.com/viewarticle/958043
88. FDA approves weekly therapy for adult growth hormone deficiency, accessed July 18, 2025, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weekly-therapy-adult-growth-hormone-deficiency
89. FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency, accessed July 18, 2025, https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-ngenlatm-long-acting-once-weekly
90. HGH controversies - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/HGH_controversies
91. Somatropin: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed July 18, 2025, https://www.drugs.com/somatropin.html
92. Somatropin Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 18, 2025, https://www.drugs.com/sfx/somatropin-side-effects.html
93. Genotropin side effects: What you should know - Medical News Today, accessed July 18, 2025, https://www.medicalnewstoday.com/articles/drugs-genotropin-side-effects
94. GENOTROPIN® (somatropin) Highlights | Pfizer Medical Information - US, accessed July 18, 2025, https://www.pfizermedicalinformation.com/genotropin/highlights
95. Norditropin (somatropin) injection - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021148s049lbl.pdf
96. Norditropin® (somatropin) Injection 10 mg - novoMEDLINK, accessed July 18, 2025, https://www.novomedlink.com/growth-related-disorders/products/treatments/norditropin/about.html
97. www.mayoclinic.org, accessed July 18, 2025, https://www.mayoclinic.org/drugs-supplements/somatropin-e-coli-derived-subcutaneous-route/description/drg-20071575#:~:text=Your%20doctor%20may%20adjust%20your,vomiting%2C%20fever%2C%20or%20lightheadedness.
98. GENOTROPIN® (somatropin) Warnings and Precautions | Pfizer Medical - US, accessed July 18, 2025, https://www.pfizermedical.com/genotropin/warnings
99. GENOTROPIN® (somatropin) Contraindications | Pfizer Medical Information - US, accessed July 18, 2025, https://www.pfizermedicalinformation.com/genotropin/contradictions
100. GENOTROPIN PATIENT BROCHURE, accessed July 18, 2025, https://www.genotropin.com/images/sites/default/files/PP-GEN-USA-0727_20-GEN-0088_Patient_Indications_Brochure_READER_DR3.pdf
101. This label may not be the latest approved by FDA. For current ..., accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019640s108lbl.pdf
102. 26.2 Growth Hormones and Suppressants - Pharmacology for Nurses | OpenStax, accessed July 18, 2025, https://openstax.org/books/pharmacology/pages/26-2-growth-hormones-and-suppressants
103. The interaction of glucocorticoids with the growth hormone-insulin-like growth factor axis and its effects on growth plate chondrocytes and bone cells - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11837502/
104. www.pfizermedical.com, accessed July 18, 2025, https://www.pfizermedical.com/genotropin/drug-interactions#:~:text=In%20addition%2C%20patients%20treated%20with,and%20prednisone%20since%20conversion%20of
105. Insulin glargine and somatropin Interactions - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/insulin-glargine-with-somatropin-1344-0-2100-0.html?professional=1
106. Growth hormone and insulin interactions - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/1292982/
107. How to Use GENOTROPIN® (somatropin) for Injection | Safety Info, accessed July 18, 2025, https://www.genotropin.com/how-to-use-genotropin
108. Genotropin (Somatropin [rDNA origin]): Side Effects, Uses, Dosage, Interactions, Warnings, accessed July 18, 2025, https://www.rxlist.com/genotropin-drug.htm
109. Omnitrope - Uses, Side Effects, Interactions - MedBroadcast.com, accessed July 18, 2025, https://medbroadcast.com/drug/getdrug/omnitrope
110. Saizen Side Effects, Uses, Interactions, Pictures, Warnings & Dosing - ScriptSave WellRx, accessed July 18, 2025, https://www.wellrx.com/saizen/drug-information/
111. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/8626872/
112. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11907490/
113. Drug Interaction Report - somatropin solifenacin - Drugs.com, accessed July 18, 2025, https://www.drugs.com/interactions-check.php?drug_list=2098-0,2100-0&professional=1
114. Drug Interaction Report: somatropin, dextromethorphan / guaifenesin - Drugs.com, accessed July 18, 2025, https://www.drugs.com/interactions-check.php?drug_list=2100-0,846-0&professional=1
115. What is the mechanism of Recombinant Somatropin? - Patsnap Synapse, accessed July 18, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-recombinant-somatropin
116. Human growth hormone produced with recombinant DNA technology - BIO Web of Conferences, accessed July 18, 2025, https://www.bio-conferences.org/articles/bioconf/pdf/2024/49/bioconf_bft2024_04009.pdf
117. Somatropin Production - Creative Biogene, accessed July 18, 2025, https://microbiosci.creative-biogene.com/somatropin-production.html
118. US8765411B2 - Process for production of recombinant human ..., accessed July 18, 2025, https://patents.google.com/patent/US8765411B2/en
119. NIH Public Access - eScholarship.org, accessed July 18, 2025, https://escholarship.org/content/qt84p931p3/qt84p931p3_noSplash_7f2fb129974160d40fa46a58457ceafb.pdf
120. Growth hormones | PPTX - SlideShare, accessed July 18, 2025, https://www.slideshare.net/slideshow/growth-hormones-236957520/236957520
121. eCopy, Inc. - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021905s000_PharmR.pdf
122. US20080050777A1 - Methods for Expression and Purification of Recombinant Human Growth Hormone - Google Patents, accessed July 18, 2025, https://patents.google.com/patent/US20080050777A1/en
123. Human growth hormone produced with recombinant DNA technology - ResearchGate, accessed July 18, 2025, https://www.researchgate.net/publication/384766888_Human_growth_hormone_produced_with_recombinant_DNA_technology
124. Somatropin (Recombinant DNA-Derived Human Growth Hormone) - NIBSC, accessed July 18, 2025, https://nibsc.org/documents/ifu/98-574.pdf
125. EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency | Pfizer, accessed July 18, 2025, https://www.pfizer.com/news/press-release/press-release-detail/ema-accepts-marketing-application-somatrogon-treat